Crossmark Global Holdings, Inc. Genmab A/S Transaction History

Crossmark Global Holdings, Inc.

$5.61 Billion
Q3 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 38,245 shares of GMAB stock, worth $787,464. This represents 0.02% of its overall portfolio holdings.

Number of Shares

38,245

Previous 70,632 45.85%

Holding current value

$787,464

Previous $1.78 Million 47.49%

% of portfolio

0.02%

Previous 0.03%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$23.84 - $28.48 $772,106 - $922,381	-32,387 Reduced 45.85%	38,245 $932,000
Q2 2024 Jul 29, 2024	BUY	$25.13 - $30.27 $181,991 - $219,215	7,242 Added 11.42%	70,632 $1.78 Million
Q1 2024 May 13, 2024	SELL	$26.43 - $32.77 $113,252 - $140,419	-4,285 Reduced 6.33%	63,390 $1.9 Million
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $171,495 - $217,530	-6,138 Reduced 8.32%	67,675 $2.16 Million
Q3 2023 Nov 08, 2023	BUY	$35.27 - $42.24 $4,761 - $5,702	135 Added 0.18%	73,813 $2.62 Million
Q2 2023 Jul 31, 2023	BUY	$37.4 - $42.94 $245,867 - $282,287	6,574 Added 9.8%	73,678 $3.11 Million
Q1 2023 May 12, 2023	BUY	$34.88 - $43.22 $228,289 - $282,874	6,545 Added 10.81%	67,104 $2.53 Million
Q4 2022 Jan 19, 2023	SELL	$33.8 - $47.06 $98,831 - $137,603	-2,924 Reduced 4.61%	60,559 $2.57 Million
Q3 2022 Nov 01, 2022	BUY	$31.52 - $373.61 $57,145 - $677,354	1,813 Added 2.94%	63,483 $2.04 Million
Q2 2022 Jul 29, 2022	BUY	$26.83 - $38.57 $34,074 - $48,983	1,270 Added 2.1%	61,670 $2 Million
Q1 2022 May 11, 2022	BUY	$30.95 - $39.68 $59,114 - $75,788	1,910 Added 3.27%	60,400 $2.19 Million
Q4 2021 Jan 10, 2022	BUY	$35.87 - $47.12 $150,654 - $197,904	4,200 Added 7.74%	58,490 $2.31 Million
Q3 2021 Oct 21, 2021	BUY	$41.55 - $48.72 $2.26 Million - $2.65 Million	54,290 New	54,290 $2.37 Million
Q3 2021 Oct 13, 2021	SELL	$41.55 - $48.72 $2.15 Million - $2.52 Million	-51,680 Closed	0 $0
Q2 2021 Jul 21, 2021	SELL	$32.88 - $44.57 $166,372 - $225,524	-5,060 Reduced 8.92%	51,680 $2.11 Million
Q1 2021 Apr 15, 2021	SELL	$30.92 - $44.4 $55,810 - $80,142	-1,805 Reduced 3.08%	56,740 $1.86 Million
Q4 2020 Jan 14, 2021	SELL	$33.66 - $40.76 $3,029 - $3,668	-90 Reduced 0.15%	58,545 $2.38 Million
Q3 2020 Oct 08, 2020	SELL	$33.07 - $38.68 $7,936 - $9,283	-240 Reduced 0.41%	58,635 $2.15 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $114,585 - $193,681	5,715 Added 10.75%	58,875 $2 Million
Q1 2020 Apr 28, 2020	BUY	$17.15 - $25.22 $153,664 - $225,971	8,960 Added 20.27%	53,160 $1.13 Million
Q4 2019 Feb 06, 2020	BUY	$18.88 - $24.14 $834,496 - $1.07 Million	44,200 New	44,200 $987,000

Others Institutions Holding GMAB

# of Institutions

236

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Genmab A/S Transaction History